Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


New Amedeo service:

Amedeo COVID-19 (formerly 2019-nCoV)

Weekly publication summary


  Breast Cancer

  Free Subscription


17.02.2020

2 Am J Surg
1 Ann Surg Oncol
1 BMC Cancer
4 Breast Cancer
1 Breast Cancer (Auckl)
2 Breast Cancer Res
9 Breast Cancer Res Treat
6 Breast J
2 Cancer
1 Cancer Chemother Pharmacol
1 Carcinogenesis
2 Clin Cancer Res
1 Eur J Surg Oncol
3 Gene
6 Int J Cancer
4 Int J Radiat Oncol Biol Phys
2 J Clin Oncol
1 J Natl Cancer Inst
2 JAMA
2 Lancet Oncol
1 N Engl J Med
2 NPJ Breast Cancer
1 Oncogene
1 PLoS One
1 Radiology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Surg

  1. BREIT C, Ablah E, Ward M, Okut H, et al
    Breast cancer risk assessment in patients who test negative for a hereditary cancer syndrome.
    Am J Surg. 2019 Nov 7. pii: S0002-9610(19)31492.
    PubMed     Text format    

  2. CHA J, McKevitt E, Pao JS, Dingee C, et al
    Access to surgery following centralization of breast cancer surgical consultations.
    Am J Surg. 2020 Jan 31. pii: S0002-9610(20)30055.
    PubMed     Text format     Abstract available


    Ann Surg Oncol

  3. SI Y, Yuan P
    ASO Author Reflections: Effect of Primary Surgery on Quality of Life in De Novo Stage IV Breast Cancer Patients.
    Ann Surg Oncol. 2020 Feb 7. pii: 10.1245/s10434-019-08130.
    PubMed     Text format    


    BMC Cancer

  4. EPPENBERGER-CASTORI S, Klingbiel D, Ruhstaller T, Dietrich D, et al
    Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99.
    BMC Cancer. 2020;20:114.
    PubMed     Text format     Abstract available


    Breast Cancer

  5. SASAKI M, Tozaki M, Rodriguez-Ruiz A, Yotsumoto D, et al
    Artificial intelligence for breast cancer detection in mammography: experience of use of the ScreenPoint Medical Transpara system in 310 Japanese women.
    Breast Cancer. 2020 Feb 12. pii: 10.1007/s12282-020-01061.
    PubMed     Text format     Abstract available

  6. MILLER EA, Pinsky PF, Heckman-Stoddard BM, Minasian LM, et al
    Breast cancer risk prediction models and subsequent tumor characteristics.
    Breast Cancer. 2020 Feb 13. pii: 10.1007/s12282-020-01060.
    PubMed     Text format     Abstract available

  7. LI J, Liu L, Feng Z, Wang X, et al
    Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype: a cohort study.
    Breast Cancer. 2020 Feb 10. pii: 10.1007/s12282-020-01058.
    PubMed     Text format     Abstract available

  8. SHIMOI T, Sagara Y, Hara F, Toyama T, et al
    First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis.
    Breast Cancer. 2020 Feb 11. pii: 10.1007/s12282-020-01054.
    PubMed     Text format     Abstract available


    Breast Cancer (Auckl)

  9. IBRAHIM AY, Youness ER, Mahmoud MG, Asker MS, et al
    Acidic Exopolysaccharide Produced from Marine Bacillus amyloliquefaciens 3MS 2017 for the Protection and Treatment of Breast Cancer.
    Breast Cancer (Auckl). 2020;14:1178223420902075.
    PubMed     Text format     Abstract available


    Breast Cancer Res

  10. BODICOAT DH, Schoemaker MJ, Jones ME, McFadden E, et al
    Correction to: Timing of pubertal stages and breast cancer risk: the Breakthrough Generations Study.
    Breast Cancer Res. 2020;22:19.
    PubMed     Text format     Abstract available

  11. GIARDIELLO D, Antoniou AC, Mariani L, Easton DF, et al
    Letter to the editor: a response to Ming's study on machine learning techniques for personalized breast cancer risk prediction.
    Breast Cancer Res. 2020;22:17.
    PubMed     Text format    


    Breast Cancer Res Treat

  12. VITIELLO GAF, Amarante MK, Banin-Hirata BK, Campos CZ, et al
    Authors' reply to the comment "Transforming growth factor beta receptor II (TGFBR2) promoter region polymorphism".
    Breast Cancer Res Treat. 2020;179:519-520.
    PubMed     Text format    

  13. ZDRAVKOVIC D, Granic M, Crnokrak B
    Proper treatment of breast angiosarcoma-mastectomy or breast conserving surgery?
    Breast Cancer Res Treat. 2020;179:765.
    PubMed     Text format    

  14. YU M, Chen Y, Wang Z, Ding X, et al
    pHLIP(Var7)-P1AP suppresses tumor cell proliferation in MDA-MB-231 triple-negative breast cancer by targeting protease activated receptor 1.
    Breast Cancer Res Treat. 2020 Feb 7. pii: 10.1007/s10549-020-05560.
    PubMed     Text format     Abstract available

  15. CHEN Z, Xu L, Shi W, Zeng F, et al
    Trends of female and male breast cancer incidence at the global, regional, and national levels, 1990-2017.
    Breast Cancer Res Treat. 2020 Feb 13. pii: 10.1007/s10549-020-05561.
    PubMed     Text format     Abstract available

  16. RYPENS C, Marsan M, Van Berckelaer C, Billiet C, et al
    Inflammatory breast cancer cells are characterized by abrogated TGFbeta1-dependent cell motility and SMAD3 activity.
    Breast Cancer Res Treat. 2020 Feb 10. pii: 10.1007/s10549-020-05571.
    PubMed     Text format     Abstract available

  17. RACHNER TD, Gobel A, Hoffmann O, Erdmann K, et al
    High serum levels of periostin are associated with a poor survival in breast cancer.
    Breast Cancer Res Treat. 2020 Feb 10. pii: 10.1007/s10549-020-05570.
    PubMed     Text format     Abstract available

  18. SARMIENTO S, McColl M, Musavi L, Gani F, et al
    Male breast cancer: a closer look at patient and tumor characteristics and factors that affect survival using the National Cancer Database.
    Breast Cancer Res Treat. 2020 Feb 10. pii: 10.1007/s10549-020-05556.
    PubMed     Text format     Abstract available

  19. SORSCHER S, Ansley K, Delaney SD, Ramkissoon S, et al
    The implications of BRCA loss of heterozygosity (LOH) and deficient mismatch repair gene (dMMR) expression in the breast cancer of a patient with both inherited breast and ovarian cancer syndrome (BRCA2) and Lynch syndrome (MLH1).
    Breast Cancer Res Treat. 2020 Feb 10. pii: 10.1007/s10549-020-05569.
    PubMed     Text format     Abstract available

  20. SUN X, Wang XE, Zhang ZP, Shi ZQ, et al
    Neoadjuvant therapy and sentinel lymph node biopsy in HER2-positive breast cancer patients: results from the PEONY trial.
    Breast Cancer Res Treat. 2020 Feb 7. pii: 10.1007/s10549-020-05559.
    PubMed     Text format     Abstract available


    Breast J

  21. LIMBACH KE, Leon E, Pommier RF, Pommier SJ, et al
    Comparison of breast cancer incidence, clinicopathologic features, and risk factor prevalence in women aged 20-29 at diagnosis to those aged 30-39.
    Breast J. 2020 Feb 14. doi: 10.1111/tbj.13783.
    PubMed     Text format    

  22. ZHAO Y, Sheng M, Zheng L, Xiong D, et al
    Application of circulating tumor DNA in breast cancer.
    Breast J. 2020 Feb 12. doi: 10.1111/tbj.13775.
    PubMed     Text format     Abstract available

  23. FERNANDEZ-GONZALEZ S, Falo C, Pla MJ, Verdaguer P, et al
    Predictive factors for omitting lymphadenectomy in patients with node-positive breast cancer treated with neo-adjuvant systemic therapy.
    Breast J. 2020 Feb 13. doi: 10.1111/tbj.13763.
    PubMed     Text format     Abstract available

  24. WANG L, Da H, Li X, Ran X, et al
    Comparison of CD4/6 inhibitors, PI3K inhibitors, and mTOR inhibitors for patients with advanced HR+/HER2- Breast cancer: A network meta-analysis of 19 RCTs.
    Breast J. 2020 Feb 9. doi: 10.1111/tbj.13780.
    PubMed     Text format    

  25. WANG L, Jorns JM
    Lymphocytic mastitis mimicking breast cancer in an elderly woman.
    Breast J. 2020 Feb 7. doi: 10.1111/tbj.13774.
    PubMed     Text format    

  26. CAO KI, Waechter L, Carton M, Kirova YM, et al
    Outcomes of exclusive radiation therapy for older women with breast cancer according to age and comorbidity status: An observational retrospective study.
    Breast J. 2020 Feb 14. doi: 10.1111/tbj.13764.
    PubMed     Text format     Abstract available


    Cancer

  27. PRINTZ C
    First person profile: Dennis J. Slamon, MD, PhD: Dr. Slamon's pioneering work helped lead to the breakthrough breast cancer drug trastuzumab, which has saved and extended the lives of millions of patients.
    Cancer. 2020;126:919-920.
    PubMed     Text format    

  28. PRINTZ C
    Experts say more women should be tested for BRCA1 and BRCA2 genetic mutations.
    Cancer. 2020;126:693.
    PubMed     Text format    


    Cancer Chemother Pharmacol

  29. POTHURI B, Brodsky AL, Sparano JA, Blank SV, et al
    Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up.
    Cancer Chemother Pharmacol. 2020 Feb 13. pii: 10.1007/s00280-020-04030.
    PubMed     Text format     Abstract available


    Carcinogenesis

  30. SHIMAMOTO K, Tanimoto K, Fukazawa T, Nakamura H, et al
    GLIS1, a novel hypoxia-inducible transcription factor, promotes breast cancer cell motility via activation of WNT5A.
    Carcinogenesis. 2020 Feb 12. pii: 5734484. doi: 10.1093.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  31. SPRING LM, Fell G, Arfe A, Sharma C, et al
    Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis.
    Clin Cancer Res. 2020 Feb 11. pii: 1078-0432.CCR-19-3492.
    PubMed     Text format     Abstract available

  32. BRANDAO M, Caparica R, Malorni L, Prat A, et al
    What is the real impact of estrogen receptor status on the prognosis and treatment of HER2-positive early breast cancer?
    Clin Cancer Res. 2020 Feb 11. pii: 1078-0432.CCR-19-2612.
    PubMed     Text format     Abstract available


    Eur J Surg Oncol

  33. POPOWICH B, Kostaras X, Temple-Oberle C
    Breast reconstruction after therapeutic or prophylactic mastectomy for breast cancer: A comparison of guideline recommendations.
    Eur J Surg Oncol. 2020 Jan 18. pii: S0748-7983(20)30043.
    PubMed     Text format     Abstract available


    Gene

  34. ABUBAKR BABTEEN N, Fawzy MS, Alelwani W, Ayiad Alharbi R, et al
    Signal peptide missense variant in cancer-brake gene CTLA4 and breast cancer outcomes.
    Gene. 2020 Feb 7:144435. doi: 10.1016/j.gene.2020.144435.
    PubMed     Text format     Abstract available

  35. NAJJARY S, Mohammadzadeh R, Mokhtarzadeh A, Mohammadi A, et al
    Role of miR-21 as an authentic oncogene in mediating drug resistance in breast cancer.
    Gene. 2020 Feb 5:144453. doi: 10.1016/j.gene.2020.144453.
    PubMed     Text format     Abstract available

  36. RAHMANI F, Ferns GA, Talebian S, Nourbakhsh M, et al
    Role of regulatory miRNAs of the PI3K/AKT signaling pathway in the pathogenesis of breast cancer.
    Gene. 2020 Feb 8:144459. doi: 10.1016/j.gene.2020.144459.
    PubMed     Text format     Abstract available


    Int J Cancer

  37. ZAHL PH, Kalager M
    Reply to: Loss of QALY in mammography screening reported by Zahl et al.
    Int J Cancer. 2020;146:1177.
    PubMed     Text format    

  38. NOME ME, Euceda LR, Jabeen S, Debik J, et al
    Serum levels of inflammation-related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers.
    Int J Cancer. 2020;146:223-235.
    PubMed     Text format     Abstract available

  39. SU L, Xu Y, Ouyang T, Li J, et al
    Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients.
    Int J Cancer. 2020 Feb 9. doi: 10.1002/ijc.32918.
    PubMed     Text format     Abstract available

  40. NJOR SH, Lynge E
    Loss of QALY in mammography screening reported by Zahl et al.
    Int J Cancer. 2020;146:1176.
    PubMed     Text format    

  41. YIN S, Wang N, Riabov V, Mossel DM, et al
    SI-CLP inhibits the growth of mouse mammary adenocarcinoma by preventing recruitment of tumor-associated macrophages.
    Int J Cancer. 2020;146:1396-1408.
    PubMed     Text format     Abstract available

  42. QI L, Zhang Q, Miao Y, Kang W, et al
    Interleukin-33 activates and recruits natural killer cells to inhibit pulmonary metastatic cancer development.
    Int J Cancer. 2020;146:1421-1434.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  43. LI R, Vora N
    Radiation Therapy for Surgically Resected Brain Metastasis: What Is Your Approach?
    Int J Radiat Oncol Biol Phys. 2019;105:938-939.
    PubMed     Text format    

  44. MENDENHALL WM, Holtzman AL, Dagan R, Bryant CM, et al
    In Regard to Sher et al.
    Int J Radiat Oncol Biol Phys. 2020;106:220-221.
    PubMed     Text format    

  45. NAOUM GE, Salama L, Niemierko A, Vieira BL, et al
    Single Stage Direct-to-Implant Breast Reconstruction Has Lower Complication Rates Than Tissue Expander and Implant and Comparable Rates to Autologous Reconstruction in Patients Receiving Postmastectomy Radiation.
    Int J Radiat Oncol Biol Phys. 2020;106:514-524.
    PubMed     Text format     Abstract available

  46. SARKAR B
    An Incorrect Impression of Dose Versus the Ischemic Cardiac Toxicity Risk Profile for Breast and Chest Wall Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2020;106:451-452.
    PubMed     Text format    


    J Clin Oncol

  47. HASSETT MJ, Somerfield MR, Baker ER, Cardoso F, et al
    Management of Male Breast Cancer: ASCO Guideline.
    J Clin Oncol. 2020 Feb 14:JCO1903120. doi: 10.1200/JCO.19.03120.
    PubMed     Text format     Abstract available

  48. MODI S, Park H, Murthy RK, Iwata H, et al
    Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
    J Clin Oncol. 2020 Feb 14:JCO1902318. doi: 10.1200/JCO.19.02318.
    PubMed     Text format     Abstract available


    J Natl Cancer Inst

  49. YAFFE MJ, Mainprize JG
    The Value of All-Cause Mortality as a Metric for Assessing Breast Cancer Screening.
    J Natl Cancer Inst. 2020 Feb 14. pii: 5736137. doi: 10.1093.
    PubMed     Text format     Abstract available


    JAMA

  50. ABBASI J
    Artificial Intelligence Improves Breast Cancer Screening in Study.
    JAMA. 2020;323:499.
    PubMed     Text format    

  51. SLAVIN SD
    Doctoring and Deportation.
    JAMA. 2020;323:119-120.
    PubMed     Text format    


    Lancet Oncol

  52. JONES RH, Casbard A, Carucci M, Cox C, et al
    Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
    Lancet Oncol. 2020 Feb 5. pii: S1470-2045(19)30817.
    PubMed     Text format     Abstract available

  53. NASRAZADANI A, Brufsky AM
    Capivasertib inhibits a key pathway in metastatic breast cancer.
    Lancet Oncol. 2020 Feb 5. pii: S1470-2045(19)30857.
    PubMed     Text format    


    N Engl J Med

  54. SHARMA P
    Major Strides in HER2 Blockade for Metastatic Breast Cancer.
    N Engl J Med. 2020;382:669-671.
    PubMed     Text format    


    NPJ Breast Cancer

  55. CARUANA D, Wei W, Martinez-Morilla S, Rimm DL, et al
    Association between low estrogen receptor positive breast cancer and staining performance.
    NPJ Breast Cancer. 2020;6:5.
    PubMed     Text format     Abstract available

  56. NORTON N, Youssef B, Hillman DW, Nassar A, et al
    Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients.
    NPJ Breast Cancer. 2020;6:4.
    PubMed     Text format     Abstract available


    Oncogene

  57. KENNEDY SP, O'Neill M, Cunningham D, Morris PG, et al
    Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer.
    Oncogene. 2020 Feb 10. pii: 10.1038/s41388-020-1202.
    PubMed     Text format     Abstract available


    PLoS One

  58. TFAILY MA, Nassar F, Sellam LS, Amir-Tidadini ZC, et al
    miRNA expression in advanced Algerian breast cancer tissues.
    PLoS One. 2020;15:e0227928.
    PubMed     Text format     Abstract available


    Radiology

  59. HEALY NA, O'Brien A, Knox M, Hargaden G, et al
    Consensus Review of Discordant Imaging Findings after the Introduction of Digital Screening Mammography: Irish National Breast Cancer Screening Program Experience.
    Radiology. 2020 Feb 11:181454. doi: 10.1148/radiol.2020181454.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: